Protara Therapeutics, Inc. PRTO Balance Sheet

Protara therapeutics, inc. (PRTO)

Balance Sheet / Yearly

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Jun'15	Mar'15	Dec'14	Sep'14	Dec'13
Assets
Current assets:
Cash and cash equivalents
36,068	564	9,349	10,813	16,763	19,371	18,225	12,485	25,356	21,170	19,986	18,385	34,132	36,392	26,678	34,186	24,062	40,031	35,983	16,817	9,784	68,840	3,239	2,793
Restricted cash
50	-	22	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred offering costs
-	121	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Available-for-sale investments
-	-	-	-	-	2,496	7,987	13,969	11,462	20,971	27,444	13,357	0	4,925	20,296	19,486	35,326	25,232	34,565	57,919	69,741	14,755	18,447	2,359
Prepaid expenses and other current assets
3,562	78	277	614	1,035	1,369	871	1,057	1,215	1,339	554	1,280	1,255	1,438	1,749	1,234	1,053	1,345	-	-	-	1,006	-	-
Prepaid expenses and other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	829	1,052	1,208	-	168	178
Other current assets
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	27	-
Short-term deposits
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	39	-
Total current assets
39,681	763	9,648	11,495	17,933	23,236	27,083	27,511	38,033	43,480	47,984	33,022	35,387	42,755	48,723	54,906	60,441	66,608	71,377	75,788	80,733	84,601	21,920	5,330
Non-current assets:
Property and equipment, net
655	458	0	83	105	263	200	219	236	259	280	309	338	372	396	374	208	224	221	102	80	83	86	62
Operating lease right-of-use asset
-	-	-	68	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use asset
391	-	-	-	135	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Goodwill
29,367	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Restricted cash
-	-	-	22	22	22	22	22	-	22	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred tax asset
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	267
Other non-current assets
-	-	-	-	-	-	100	100	240	218	300	300	299	393	276	383	693	706	686	685	114	114	2,173	-
Total assets
70,096	1,222	9,648	11,600	18,060	23,521	27,405	27,852	38,509	43,979	48,564	33,631	36,024	43,520	49,395	55,663	61,342	67,538	72,284	76,575	80,927	84,798	24,179	5,659
Liabilities and Stockholders' Equity (Deficit)
Current liabilities:
Convertible notes, including accrued interest of $0 and $112 as of December 31, 2014 and 2013, respectively
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	3,727
Derivative liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,443
Accounts payable
2,649	715	394	60	1,676	441	385	431	7,016	291	226	1,193	474	556	591	527	431	1,020	591	502	1,205	917	1,048	399
Accrued expenses
995	2,634	1,219	1,995	1,559	2,637	2,149	1,800	2,004	8,949	8,868	2,944	2,549	4,523	4,186	3,970	2,838	2,576	2,235	2,202	1,429	1,421	1,610	984
Short-term debt
1,297	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Right-of-use liability, current
24	-	-	68	135	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	98	241	319	537	342	61	-	0	-	-
Deferred tax liability
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	267
Current portion of deferred revenue from sale of option to acquire company
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,948
Total current liabilities
4,967	3,350	1,613	2,123	3,370	3,078	2,534	2,231	9,020	9,240	9,094	4,137	3,023	5,079	4,942	4,738	3,588	4,133	3,168	2,765	2,634	2,338	2,658	9,768
Non-current liabilities:
Right-of-use liability, long-term
386	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other non-current liabilities
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	84	51	-	-	-	-
Investors' rights/obligations
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	11,903	-
Total liabilities
5,354	3,350	1,613	2,123	3,370	3,078	2,534	2,231	9,020	9,240	9,094	4,137	3,023	5,079	4,942	4,738	3,588	4,133	3,252	2,816	2,634	2,338	14,561	9,768
Commitments and Contingencies (Note 6)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders' Equity (Deficit)
Redeemable convertible preferred stock,
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	35,416	-
Preferred Stock, $0.001 par value, authorized 10,000,000 shares: Series 1 Convertible Preferred Stock, 3,880 and 0 shares authorized at March 31, 2020 and December 31, 2019, respectively, 3,879 and 0 shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively.
0	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0	0	0	-	0
Common Stock, $0.001 par value, authorized 100,000,000 shares: Common Stock, 5,843,203 and 2,627,533 common shares issued and outstanding as of March 31, 2020 and December 31, 2019, respectively.
5	2	19	19	19	-	19	18	18	18	18	18	17	17	17	16	16	16	16	16	16	16	-	-
Additional Paid in Capital
87,577	10,651	210,683	210,587	210,486	209,385	208,536	204,780	203,774	202,953	202,113	201,366	199,259	198,201	197,310	196,607	195,529	194,651	193,919	193,266	192,731	192,324	-	-
Accumulated Deficit
-22,841	-12,781	-223,852	-222,316	-217,001	-210,470	-205,211	-200,701	-195,822	-189,741	-184,190	-171,883	-166,275	-159,777	-152,815	-145,708	-137,803	-131,251	-124,909	-119,526	-114,454	-109,874	-116,540	-100,514
Accumulated other comprehensive income
-	-	2	4	3	5	4	1	-4	-14	-7	-7	-	0	8	10	12	-11	6	3	-	-6	-11	-
Total Stockholders' Equity (Deficit)
64,741	-2,127	8,035	9,477	14,690	20,443	24,871	25,621	29,489	34,739	39,470	29,494	33,001	38,441	44,453	50,925	57,754	63,405	69,032	73,759	78,293	82,460	-116,551	-100,514
Total Liabilities and Stockholders' Equity (Deficit)
70,096	1,222	9,648	11,600	18,060	23,521	27,405	27,852	38,509	43,979	48,564	33,631	36,024	43,520	49,395	55,663	61,342	67,538	72,284	76,575	80,927	84,798	24,179	5,659
Series A Convertible Preferred Stock [Member]
Preferred stock, $0.001 par value per share; 10,000,000 shares authorized at December 31, 2019 and 2018:Series A convertible preferred stock 22,000 shares authorized at December 31, 2019 and December 31, 2018; 18,954 and 22,000 issued and outstanding at December 31, 2019 and at December 31, 2018, respectively
-	-	21,183	21,183	21,183	21,523	-	-	-	21,523	-	-	-	-	-	-	-	-	-	-	-	-	-	-